secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-05-28T20:05:08+00:00
Accession:  0001193125-26-245186
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Viridian pre-pays $55.1M Hercules Capital loan, terminates credit facility
--------------------------------------------------------------------------

- Paid ~$55.1M to satisfy all principal, accrued interest and fees under Loan Agreement with Hercules Capital.
- Original term loan allowed up to $300M; company borrowed $50M at floating rate (min 8.95%, cap 9.45%).
- Loan termination effective May 27, 2026; all obligations discharged and covenants eliminated.
- Interest-only payments were due through Oct 2029/2030 depending on milestones; now fully extinguished.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526245186/0001193125-26-245186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526245186/d111506d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-245186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer